Blood Disorders & Hematology Clinical Trials Update: Week 14, 2026

Published April 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

This large phase III trial led by the Children's Oncology Group looked at different chemotherapy plans tailored to the risk level of younger patients with standard-risk acute lymphoblastic leukemia or localized B-lineage lymphoblastic lymphoma. The goal was to find treatments that work well but may cause fewer side effects, improving both survival and quality of life. Results from many sites worldwide provide important information for future treatment choices in this group.

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Conducted by University College London, this phase 3 study is testing whether chemotherapy alone or combined with radiotherapy works best for patients with early stage Hodgkin lymphoma. By using PET scans to guide treatment decisions, the trial aims to reduce unnecessary radiation and its side effects while maintaining strong outcomes. The study is actively recruiting patients internationally and will follow them for at least five years to track long-term results.

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

This phase 3 trial in France is exploring a new treatment combination for people newly diagnosed with multiple myeloma who are eligible for stem cell transplant. Adding elranatamab and lenalidomide after initial therapy could improve how well patients respond and maintain their remission, possibly offering a better alternative to current maintenance treatments. Over 800 patients are expected to take part, making this a significant study for multiple myeloma care.

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

This international phase 3 trial tested whether adding tafasitamab and lenalidomide to the standard R-CHOP chemotherapy improves outcomes for adults newly diagnosed with aggressive diffuse large B-cell lymphoma. The study aims to provide a stronger treatment option for patients with high-risk disease. Conducted in multiple countries, the trial’s findings could influence future lymphoma treatment strategies.

Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

This phase 3 trial involved nearly 3,000 children and adolescents with classical Hodgkin lymphoma from 19 countries. The study focused on balancing effective treatment with lowering radiation exposure to minimize long-term side effects. Although enrollment is complete, results are still pending and will be important for shaping safer treatment approaches for young patients.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.